AstraZeneca's $15 billion pledge to its China operations highlights the country's advantages. But other regions are also hoping to host more clinical studies.
Investor's Business Daily on MSN
China biotech lights up. US stocks prepare for a new powerhouse.
U.S.-based biotech stocks are closely watching the China's rapid advance into the biotech field. Will they withstand the ...
Beijing's ambition to move up the value chain could see it becoming a major exporter of digital services, AI to global ...
China and Climate” tracks and breaks down China’s engagement with climate and energy issues around the world. Major climate ...
China's integration into global industrial and supply chains through two-way investment is acting as a significant catalyst ...
China's Ambassador to India, Xu Feihong, "renewed momentum" in India-China relations by blending cultural reflections with ...
Noncompete agreements are important tools that employers can use to protect proprietary assets, such as goodwill, customer relationships, employee relationships, trade secrets, and other confidential ...
Asked by a foreign media regarding that in early 2026, multiple foreign leaders have already visited China, and how much investment in China these visits have helped generate, He Yadong, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results